Kristian Reich - 27 Feb 2025 Form 4 Insider Report for MoonLake Immunotherapeutics (MLTX)

Role
Chief Scientific Officer
Signature
/s/ Matthias Bodenstedt, Attorney-in-fact for Kristian Reich
Issuer symbol
MLTX
Transactions as of
27 Feb 2025
Net transactions value
$0
Form type
4
Filing time
03 Mar 2025, 21:07:32 UTC
Previous filing
22 Jan 2025
Next filing
04 Sep 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MLTX Stock Option (Right to Buy) Award $0 +139,273 $0.000000 139,273 27 Feb 2025 Class A ordinary shares, par value $0.0001 per share 139,273 $41.77 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option represents a right to purchase a total of 139,273 of the Issuer's Class A ordinary shares, vesting in four equal annual installments on February 27, 2026, 2027, 2028 and 2029, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date.